{"id":"NCT01423617","sponsor":"InQpharm Group","briefTitle":"Efficacy and Safety of Zenoctil in Reducing Body Weight","officialTitle":"Double-blind, Randomized, Placebo-controlled, Bicentric Study to Evaluate the Safety and Efficacy of Zenoctil in Reducing Body Weight of Overweight Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2011-08-26","resultsPosted":"2015-04-23","lastUpdate":"2015-04-23"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Overweight"],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"Zenoctil","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Zenoctil","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The intention of the study is to evaluate the safety and potential body weight and body fat loss effects of a 12-week treatment with Zenoctil in a randomized, double-blind, placebo-controlled, parallel study conducted in Caucasian subjects.\n\nThis study will also include a diet plan for each subject, calculated based on gender, age, and energy requirements; and adjusted to be slightly hypocaloric.","primaryOutcome":{"measure":"Change in Mean Body Weight (kg)","timeFrame":"12 weeks","effectByArm":[{"arm":"Zenoctil","deltaMin":-2.26,"sd":2.37},{"arm":"Placebo","deltaMin":-0.56,"sd":2.45}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":21},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":[]}}